What is Wedbush's Forecast for SAGE Q1 Earnings?

Sage Therapeutics, Inc. (NASDAQ:SAGE - Free Report) - Equities researchers at Wedbush issued their Q1 2026 earnings per share (EPS) estimates for shares of Sage Therapeutics in a research report issued to clients and investors on Wednesday, April 16th. Wedbush analyst L. Chico forecasts that the biopharmaceutical company will post earnings of ($0.75) per share for the quarter. Wedbush has a "Neutral" rating and a $6.00 price objective on the stock. The consensus estimate for Sage Therapeutics' current full-year earnings is ($3.52) per share. Wedbush also issued estimates for Sage Therapeutics' Q2 2026 earnings at ($0.72) EPS, Q3 2026 earnings at ($0.69) EPS and Q4 2026 earnings at ($0.65) EPS.

A number of other equities analysts have also recently commented on the company. Needham & Company LLC reissued a "hold" rating on shares of Sage Therapeutics in a report on Wednesday, February 12th. Bank of America began coverage on shares of Sage Therapeutics in a report on Tuesday, March 11th. They set an "underperform" rating and a $5.00 price target on the stock. Piper Sandler lowered their price target on shares of Sage Therapeutics from $26.00 to $9.00 and set an "overweight" rating for the company in a report on Thursday, January 2nd. Scotiabank cut their target price on shares of Sage Therapeutics from $14.00 to $12.00 and set a "sector outperform" rating on the stock in a research report on Wednesday, February 12th. Finally, Canaccord Genuity Group decreased their target price on shares of Sage Therapeutics from $9.00 to $8.00 and set a "hold" rating for the company in a research report on Wednesday, February 12th. Three research analysts have rated the stock with a sell rating, fifteen have given a hold rating and two have given a buy rating to the stock. According to data from MarketBeat.com, Sage Therapeutics currently has an average rating of "Hold" and a consensus target price of $8.81.

Sage Therapeutics Price Performance

NASDAQ:SAGE traded up $0.15 during mid-day trading on Thursday, reaching $7.59. The stock had a trading volume of 395,765 shares, compared to its average volume of 1,224,364. The stock has a 50-day simple moving average of $7.48 and a two-hundred day simple moving average of $6.72. Sage Therapeutics has a 12 month low of $4.62 and a 12 month high of $14.97. The stock has a market capitalization of $466.33 million, a PE ratio of -1.15 and a beta of 0.48.

Sage Therapeutics (NASDAQ:SAGE - Get Free Report) last announced its quarterly earnings data on Tuesday, February 11th. The biopharmaceutical company reported ($1.56) earnings per share (EPS) for the quarter, missing analysts' consensus estimates of ($1.54) by ($0.02). Sage Therapeutics had a negative return on equity of 68.18% and a negative net margin of 971.50%.

Institutional Trading of Sage Therapeutics

A number of hedge funds have recently modified their holdings of the business. Wealth Enhancement Advisory Services LLC bought a new position in shares of Sage Therapeutics during the first quarter valued at approximately $347,000. Pallas Capital Advisors LLC purchased a new position in Sage Therapeutics during the first quarter valued at $166,000. Merit Financial Group LLC bought a new stake in Sage Therapeutics in the first quarter worth $87,000. GAMMA Investing LLC increased its stake in Sage Therapeutics by 16,118.0% during the 1st quarter. GAMMA Investing LLC now owns 8,109 shares of the biopharmaceutical company's stock valued at $64,000 after purchasing an additional 8,059 shares in the last quarter. Finally, Toronto Dominion Bank bought a new stake in shares of Sage Therapeutics during the fourth quarter valued at approximately $742,000. Institutional investors own 99.22% of the company's stock.

Sage Therapeutics Company Profile

Sage Therapeutics, Inc, a biopharmaceutical company, develops and commercializes brain health medicines. Its product candidates include ZULRESSO, a CIV injection for the treatment of postpartum depression (PPD) in adults; and ZURZUVAE, a neuroactive steroid, a positive allosteric modulator of GABAA receptors, targeting both synaptic and extrasynaptic GABAA receptors, for the treatment of postpartum depression.